Outil d'établissement de liens pour les subventions d'équipe La biologie au service de la prévention du cancer
Les subventions d'équipe La biologie au service de la prévention du cancer visent à mobiliser des équipes de recherche interdisciplinaires qui aspirent à faire progresser, dans une optique biologique et mécaniste, l'étiologie du cancer et la compréhension des divers facteurs de risque associés (hôte, mode de vie, environnement, contexte social, etc.) dans l'espoir de mettre en évidence de nouvelles cibles et méthodes pour prévenir la maladie, la détecter tôt et réduire ses risques d'apparition.
L'outil d'établissement de liens a vocation à mettre en relation les candidats au concours et à faciliter la formation des équipes de recherche et l'élaboration des demandes.
Il s'adresse aux chercheurs, aux utilisateurs des connaissances (c.-à-d. les personnes ayant une expérience concrète, les praticiens et les responsables des politiques) et aux partenaires candidats qui souhaitent échanger des renseignements ou établir une collaboration dans le cadre de la possibilité de financement. Pour être inclus dans l'outil, veuillez remplir le formulaire créé à cet effet. Les informations que vous transmettrez figureront dans le tableau ci-dessous. Ce dernier sera mis en ligne et fera l'objet de mises à jour régulières.
L'utilisation de l'outil d'établissement de liens ne constitue pas une exigence du processus de présentation d'une demande et ne procure aucun avantage particulier dans l'évaluation et le financement des demandes. Il n'est donc pas obligatoire de communiquer avec les personnes qui ont rendu leur information publique à l'aide de l'outil.
En remplissant le formulaire, vous consentez par ailleurs à ce que son contenu soit publié en l'étatNote en bas de page * dans la langue dans laquelle il a été soumis (français ou anglais). Sachez que vous pouvez à tout moment soumettre une demande de modification ou de retrait de vos renseignements en écrivant à cihr.icr@uhn.ca. Les demandes seront traitées périodiquement.
N'hésitez pas à adresser toute question au sujet du formulaire ou de l'outil à cihr.icr@uhn.ca.
Avis
L'information est fournie dans la langue dans laquelle le répondant l'a présentée.
| Coordonnées | Catégorie d'intervenants | Classe(s) de financement d'intérêt | Domaine de recherche et d'expertise | Renseignements complémentaires |
|---|---|---|---|---|
|
Isabelle Plante |
Researcher |
|
My research program aims to determine the effects of exposure to endocrine disruptive compounds (EDCs) on mammary gland development and breast cancer, and to determine the toxicity mechanisms involved. To do so, we use in vivo models combined with innovative in vitro 3D models, as well as zebrafish. We also have projects involving occupational exposure in humans. The results obtained with these different types of models are analyzed by histological, proteomic, transcriptomic and functional approaches. |
|
|
Walid Houry |
Researcher |
|
My group has been studying the mitochondrial ClpP protease and its role in cancer, and has been developing compounds targeting the protease to be used as novel anticancers. We have been testing these compounds in breast cancers. However, the compounds also seem to be promising for glioblastomas. |
My group's expertise is in protein biochemistry and structural biology, cell biology, and drug discovery. I am interested in testing the ClpP-targeting compounds in animal models and patient tissue. As such, I am interested in collaborating with groups that have animal expertise as well as clinical expertise, and that have access to patient tissue samples. |
|
Talía Malagón |
Early career researcher Researcher |
|
Epidemiologist, health decision modeller, and population scientist specializing in cancer screening and early cancer detection, mostly in the context of cervical cancer. Research interests include:
|
I am looking to build connections and partner with other researchers as a co-applicant in an interdisciplinary team for this funding opportunity in research projects focused on cancer diagnosis and early detection/screening. I can contribute to research teams as an early career researcher (ECR) and as an expert in either pillar 3 (health services research) or pillar 4 (Social, cultural, environmental and population health research) to fulfill the requirements of this funding opportunity. |
|
Ahouehome sehouenou Albéric Candide |
Épidémiologiste titulaire d'une maitrise en quête d'une opportunité de projet doctoral |
|
Épidémiologie, biostatistique, Santé publique et imagerie médicale |
Je désire poursuivre un projet doctoral en épidémiologie avec potentiellement des chercheurs expérimentés en biostatistiques en lien avec les projets sur le cancer, l'intelligence artificielle, en biologie du cancer. |
|
Subburaj Ilangumaran |
Researcher |
|
|
We would like exploit our tissue-specific SOCS1 deficient mouse models that are more sensitive to develop liver and prostate cancers than wild type mice to assess the pro-carcinogenic effects of food additives and the antagonistic effects of dietary, probiotic and post-biotic interventions. We are specifically looking for
|
|
Alexander Baker, Ph.D. |
Early career researcher |
Breast cancer |
We develop advanced in vitro models to study breast cancer, emphasizing how extracellular matrix (ECM) composition affects drug responses and the immune system. Central to our approach is synthesizing biopolymers and incorporating cell-adhesive peptides to create 3D environments mimicking the tumor microenvironment. We leverage 3D tumor models, previously including patient-derived organoids (PDOs) and xenografts (PDXs), to explore tumor behavior and validate findings. Through drug screening, we aim to identify therapeutic targets and improve drug response predictions towards precision medicine. |
We aim to establish collaborations with experts in immunology, computational modeling, and bioinformatics to enhance the analysis of drug-immune interactions within our in vitro models. We also seek team members with expertise in advanced imaging techniques, and clinical oncology to integrate diverse perspectives into our research. Our proposed focus includes novel proteolysis targeting chimeras (PROTACs), investigating how ECM composition modulates metastasis, immune cell activity, and drug efficacy in breast cancer to identify biomarkers and therapeutic targets for personalized treatment. |
|
Hamid Ghaedi |
|
|
My research integrates bioinformatics, computational genomics, and multi-omics data analysis to uncover novel biomarkers and pathways in cancer prevention and progression. I specialize in analyzing bulk and single-cell RNA-seq datasets, developing scalable workflows for genomic data, and building predictive models using machine learning. My work supports clinical trials by identifying therapy-related transcriptional programs and linking genomic markers to patient outcomes. With expertise in cancer genomics and computational tools, I seek collaborative opportunities to advance precision approaches in cancer prevention and early detection. |
I am seeking to join a collaborative, multidisciplinary team where I can contribute my expertise in bioinformatics and cancer genomics. Earlier in 2024, I helped secure a $2.5M grant and currently lead bioinformatics analyses on bladder cancer single-cell RNA-seq and whole exome sequencing data. I aim to apply advanced computational approaches to uncover novel biomarkers and pathways for cancer prevention and early detection. I am eager to contribute to innovative, team-driven projects in this funding opportunity. |
|
Mitra Tabatabaee |
Early career researcher | General pool |
I am molecular biologist, who is looking for molecular mechanisms underlying cancer progression and metastasis, specifically in astrocytoma and gliomas. |
|
|
Paola Marignani |
Researcher |
|
Areas of expertise include single-cell RNAseq analysis in primary tumours and tumours from animal models. We apply computational analysis and machine learning algorithms for identifying unique genes and tumour heterogeneity. Areas of signalling expertise include cancer metabolism, LKB1/AMPK/mTOR signalling networks, HER2 receptor signalling, SMARCA4 signalling, mitochondria metabolism. Animal models include: spontaneous mouse models of HER2+ breast cancer, lung cancer and dementia models. |
|
|
Canadian Partnership Against Cancer |
Applicant partner | As the steward of the Canadian Strategy for Cancer Control (the Strategy), the Canadian Partnership Against Cancer (the Partnership) receives ongoing funding from Health Canada to work with provincial and territorial ministries of health and their cancer programs, health system leaders and clinicians, and people affected by cancer across Canada to implement the Strategy to improve cancer outcomes for all people in Canada. |
The Canadian Partnership Against Cancer's OncoSim is available for projects aimed at achieving the goals of the Canadian Strategy for Cancer Control. The OncoSim microsimulation model projects health and economic outcomes for various cancers, enabling users to create and compare scenarios with results that inform cancer service planning. In-kind support includes:
|
|
|
Providence Therapeutics |
Applicant partner | Providence Therapeutics (PTx) is an mRNA Medicines Platform company operating in the RNA field for 10 years. PTx has developed platforms for mRNA and lipid nanoparticle (LNP) medicines that stimulate immune responses to cancers and infectious diseases. Additionally, PTx is able to manufacture vaccines and therapeutics from personalized to pandemic scale. PTx's preclinical pipeline includes programs in oncology, infectious diseases, and animal health, developed both internally and with academic and industry partners. Furthermore, PTx has collaborations with UHN and OICR for research translation on the PTx platform. | Providence Therapeutics offers a comprehensive mRNA Medicines Platform to interested researchers. PTx is committed to leveraging the potential of mRNA technology for the development of innovative mRNA medicines. PTx invites researchers to utilize its proven mRNA platform and LNP technology to translate their discoveries into clinical applications. | |
|
Health Canada's Food and Nutrition Directorate |
Applicant partner | Ultra-processed foods |
Health Canada is the Federal department responsible for helping Canadians maintain and improve their health. Within Health Canada, the Food and Nutrition Directorate has the mandate to:
The Food and Nutrition Directorate includes the Bureau of Chemical Safety and Bureau of Nutritional Sciences. |
Health Canada is interested in projects that aim to better elucidate potential pathways by which ingredients or other substances in ultra-processed foods may affect biological mechanisms related to cancer risk or development. In-kind support may include:
|
|
Canadian Nuclear Laboratories |
Applicant partner | The Canadian Nuclear Laboratories (CNL) is Canada's premier nuclear science and technology organization, and a world leader in developing nuclear technology for peaceful and innovative applications. Using our unique expertise, we are restoring and protecting the environment, we are advancing clean energy technology, and our medical breakthroughs continue to improve the health of people around the world. CNL's unique Biological Research Facility and irradiation capabilities enable iconic long-term in vivo studies of impact of radiation on health. For 75 years, CNL has been at the forefront of innovation in nuclear medicine, radiopharmaceuticals, and low dose radiation research. |
CNL is interested in projects that aim to prevent cancer due to chronic exposure to low dose ionizing radiation that may happen in the environment, such as radon emission, in the workplace, or during repeated medical procedures. In-kind support may include:
|
- Date de modification :